You just read:

Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Sustained Dose-Related Target Engagement Activity in a Multiple Ascending Dose Phase 1 Study

News provided by

Protagonist Therapeutics, Inc.

Aug 01, 2019, 16:30 ET